{"id":"https://openalex.org/W85665266","doi":"https://doi.org/10.1182/blood.v122.21.1832.1832","title":"The Potent PI3K-\u03b4,\u03b3 Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines","display_name":"The Potent PI3K-\u03b4,\u03b3 Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W85665266","doi":"https://doi.org/10.1182/blood.v122.21.1832.1832","mag":"85665266"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.1832.1832","doi":"https://doi.org/10.1182/blood.v122.21.1832.1832","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.1832.1832","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027467829","display_name":"Veronica T. Campbell","orcid":"https://orcid.org/0009-0001-8700-560X","observed_orcids":["https://orcid.org/0009-0001-8700-560X"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Veronica Campbell","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019901628","display_name":"Ryan C. Thompson","orcid":"https://orcid.org/0000-0002-0450-8181","observed_orcids":["https://orcid.org/0000-0002-0450-8181"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Thompson","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002904500","display_name":"Vivian Villegas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivian Villegas","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112500666","display_name":"Jennifer Proctor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Proctor","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085672356","display_name":"Karen McGovern","orcid":"https://orcid.org/0000-0002-2578-3975","observed_orcids":["https://orcid.org/0000-0002-2578-3975"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen McGovern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005876566","display_name":"Jeffery Lorne Kutok","orcid":"https://orcid.org/0009-0009-9931-3106","observed_orcids":["https://orcid.org/0009-0009-9931-3106"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffery L. Kutok","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5028575353","display_name":"Howard Marvin Stern","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard M. Stern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210108457"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.00766543,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"122","issue":"21","first_page":"1832","last_page":"1832"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9003999829292297,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9003999829292297,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0697999969124794,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.01489999983459711,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.7910000085830688},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/molecular-subtypes","display_name":"molecular subtypes","score":0.6190000176429749},{"id":"https://openalex.org/keywords/germinal-center-b-cell-like-subtype","display_name":"germinal center B-cell subtype","score":0.8130000233650208},{"id":"https://openalex.org/keywords/activated-b-cell-like-subtype","display_name":"activated B-cell-like subtype","score":0.9869999885559082},{"id":"https://openalex.org/keywords/b-cell-receptor-signaling","display_name":"B cell receptor signaling","score":0.7160000205039978},{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.7950000166893005},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.5699999928474426},{"id":"https://openalex.org/keywords/cell-growth-inhibition","display_name":"cell growth inhibition","score":0.5},{"id":"https://openalex.org/keywords/akt","display_name":"Akt","score":0.3700000047683716}],"concepts":[{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.728284478187561},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6574445366859436},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.6335214376449585},{"id":"https://openalex.org/C43907098","wikidata":"https://www.wikidata.org/wiki/Q903924","display_name":"breakpoint cluster region","level":3,"score":0.5416404008865356},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5203077793121338},{"id":"https://openalex.org/C96926380","wikidata":"https://www.wikidata.org/wiki/Q1737968","display_name":"Germinal center","level":4,"score":0.48079100251197815},{"id":"https://openalex.org/C2780790343","wikidata":"https://www.wikidata.org/wiki/Q5090610","display_name":"Chemoimmunotherapy","level":4,"score":0.4768993854522705},{"id":"https://openalex.org/C2781322055","wikidata":"https://www.wikidata.org/wiki/Q423725","display_name":"Phosphoinositide 3-kinase","level":4,"score":0.4765753746032715},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.45508792996406555},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.4499548077583313},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.40613630414009094},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3712809085845947},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2886672019958496},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.20253312587738037},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.20019447803497314},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.1993941366672516},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.10120576620101929},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.1832.1832","doi":"https://doi.org/10.1182/blood.v122.21.1832.1832","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.1832.1832","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2551966143","https://openalex.org/W4243256516","https://openalex.org/W2789812443","https://openalex.org/W2560963837","https://openalex.org/W2307723713","https://openalex.org/W2134797116","https://openalex.org/W2756389342","https://openalex.org/W2737525285","https://openalex.org/W2592558314","https://openalex.org/W2602310116"],"abstract_inverted_index":{"Abstract":[0],"Diffuse":[1],"large":[2],"B-cell":[3,78],"lymphoma":[4,13],"(DLBCL)":[5],"is":[6,138,168,586],"the":[7,28,38,150,165,181,188,221,261,321,458,536,542,615],"most":[8],"common":[9],"form":[10],"of":[11,19,22,40,164,172,183,190,197,204,227,287,308,323,327,337,354,430,450,460,492,512,577,617],"non-Hodgkin":[12],"(NHL).":[14],"Despite":[15],"aggressive":[16],"chemoimmunotherapy,":[17],"\u223c40%":[18],"patients":[20,156,579,613],"die":[21],"their":[23],"disease.":[24],"Molecular":[25],"differences":[26],"in":[27,122,149,155,180,193,260,299,316,340,420,443,457,469,525,535,541,556,564,565],"tumor":[29],"genome":[30],"are":[31,92,119,129,426,550],"likely":[32],"to":[33,37,109,257,279,389,401,417,552,588,591,606],"be":[34,604],"major":[35],"contributors":[36],"heterogeneity":[39],"clinical":[41,147],"response.":[42],"Several":[43],"investigators":[44],"have":[45],"identified":[46],"molecular":[47,206,231,297],"subtypes,":[48],"including":[49,242],"a":[50,70,100,139,195,228,234,288,335,466,506,520,526,575],"\u201ccell-of-origin\u201d":[51],"(COO)":[52],"signature":[53,74],"with":[54,75,157,210,230,306,379,403,445,496,501,531,546,614],"activated":[55],"B-cell-like":[56,61],"(ABC)":[57],"and":[58,69,81,116,124,135,176,213,248,250,267,275,293,330,345,397,514,540,619],"germinal":[59],"center":[60],"(GCB)":[62],"sub-types":[63,84],"(Alizadeh,":[64],"et":[65,86],"al.":[66,87],"Nature":[67],"2000),":[68],"\u201cconsensus":[71],"clustering\u201d":[72],"(CC)":[73],"oxidative":[76],"phosphorylation,":[77,375],"receptor":[79],"(BCR)/proliferation,":[80],"host":[82],"response":[83],"(Monti,":[85],"2005).":[88],"Phosphoinositide-3":[89],"kinases":[90],"(PI3Ks)":[91],"key":[93],"cellular":[94,235,527],"signaling":[95,175,192,415],"proteins":[96],"that":[97,144,411,432,574,601],"act":[98],"as":[99,113,312,488,561,563],"central":[101],"node,":[102],"relaying":[103],"signals":[104],"from":[105],"cell":[106,132,202,223,240,269,342,370,383,422,485,538,544,559],"surface":[107],"receptors":[108],"downstream":[110],"mediators":[111],"such":[112,487],"AKT.":[114],"PI3K-\u03b4":[115,212],"PI3K-\u03b3":[117,214],"isoforms":[118],"preferentially":[120],"expressed":[121,216],"normal":[123,173],"malignant":[125],"leukocytes":[126],"where":[127],"they":[128],"critical":[130],"for":[131,510,611],"differentiation,":[133],"migration,":[134],"proliferation.":[136],"IPI-145":[137,258,280,291,302,338,390,402,418,434,438,476,532,618],"potent,":[140],"oral":[141],"PI3K-\u03b4,\u03b3":[142,513],"inhibitor":[143,449],"has":[145,177],"shown":[146],"activity":[148,439],"Phase":[151],"1":[152,251],"trial":[153],"(IPI-145-02)":[154],"advanced":[158],"hematologic":[159],"malignancies":[160],"(ClinicalTrials.gov":[161],"NCT01476657).":[162],"Activation":[163],"PI3K":[166,191,309],"pathway":[167,310,324,414],"an":[169,447],"important":[170],"component":[171],"BCR":[174,364,392,404,413,461,547],"been":[178],"implicated":[179],"pathogenesis":[182],"DLBCL.":[184,595],"To":[185,319],"further":[186],"explore":[187,553],"role":[189],"DLBCL,":[194],"panel":[196],"more":[198],"than":[199],"10":[200],"DLBCL":[201,222,421,436,558,567,578,612],"lines":[203,241,270,371,560],"varying":[205,218],"profile":[207,298],"was":[208,284,332,356,377,386,440,472,494,523],"treated":[209],"IPI-145.":[211,380,502],"were":[215,255,277,347],"at":[217],"levels":[219],"across":[220],"lines,":[224,486],"without":[225,391],"evidence":[226,286,307,599],"correlation":[229,289],"subtype.":[232],"In":[233,483,596],"growth":[236,528],"inhibition":[237,311,491,529],"assay,":[238],"5":[239,268],"4":[243],"GCB":[244,382],"(SU-DHL-4,":[245],"SU-DHL-6,":[246],"OCI-LY-8,":[247],"WSU-DLCL-2)":[249],"ABC":[252],"(Ri-1)":[253],"subtype":[254],"sensitive":[256,388],"treatment":[259,339,498],"micromolar":[262],"(\u03bcM)":[263],"range":[264],"or":[265,295],"below,":[266],"(OCI-LY-3,":[271],"OCI-LY-7,":[272],"Pfeiffer,":[273],"Toledo":[274],"U2932)":[276],"insensitive":[278],"(IC50":[281],">25\u03bcM).":[282],"There":[283],"no":[285],"between":[290],"sensitivity":[292,303,400,419],"COO":[294],"CC":[296],"this":[300,518,554],"panel.":[301],"did":[304],"correlate":[305],"measured":[313],"by":[314,349,475,481],"reduction":[315],"phospho":[317],"(p)-AKT.":[318],"characterize":[320],"kinetics":[322],"modulation,":[325],"phosphorylation":[326],"AKT,":[328],"PRAS40,":[329],"S6":[331],"examined":[333],"following":[334],"time-course":[336],"selected":[341],"lines.":[343,423],"P-AKT":[344],"p-PRAS40":[346],"modulated":[348],"30":[350],"minutes,":[351],"whereas":[352],"modulation":[353],"p-S6":[355],"not":[357,500],"detected":[358],"until":[359],"after":[360],"8":[361],"hours.":[362],"Upon":[363],"stimulation":[365],"via":[366],"antibody-induced":[367],"crosslinking,":[368,462],"some":[369],"exhibited":[372,398,465],"enhanced":[373,399],"AKT":[374],"which":[376,471],"inhibited":[378,474,480],"The":[381],"line":[384,539,545],"OCI-LY-8":[385,463,543],"moderately":[387],"crosslinking":[393,405],"(low":[394],"\u03bcM":[395],"range)":[396],"(sub-\u03bcM":[406],"range).":[407],"These":[408,503],"results":[409],"suggest":[410,505,573],"intact":[412],"contributes":[416],"Current":[424],"efforts":[425],"focusing":[427],"on":[428],"identification":[429],"biomarkers":[431],"define":[433],"responsive":[435],"subsets.":[437],"also":[441],"explored":[442],"combination":[444,511,521,555,616],"ibrutinib,":[446],"irreversible":[448],"Bruton":[451],"agammaglobulinemia":[452],"tyrosine":[453],"kinase":[454],"(BTK).":[455],"Interestingly,":[456],"setting":[459],"cells":[464],"robust":[467,490],"increase":[468],"p-AKT":[470],"completely":[473],"but":[477,499],"only":[478],"partially":[479],"ibrutinib.":[482,620],"other":[484],"SU-DHL-4,":[489],"p-BTK":[493],"observed":[495,524],"ibrutinib":[497,534],"findings":[504,572],"potential":[507],"mechanistic":[508],"rationale":[509],"BTK":[515],"inhibition.":[516,583],"Supporting":[517],"hypothesis,":[519],"effect":[522],"assay":[530],"plus":[533],"SU-DHL-4":[537],"crosslinking.":[548],"Studies":[549],"ongoing":[551],"additional":[557],"well":[562],"vivo":[566],"models.":[568],"Taken":[569],"together,":[570],"these":[571],"subset":[576],"might":[580],"benefit":[581],"fromPI3K-\u03b4,\u03b3":[582],"Additional":[584],"work":[585],"necessary":[587],"determine":[589],"how":[590],"prospectively":[592],"identify":[593],"IPI-145-sensitive":[594],"addition,":[597],"preliminary":[598],"suggests":[600],"there":[602],"may":[603],"opportunities":[605],"improve":[607],"targeted":[608],"therapy":[609],"options":[610],"Disclosures:":[621],"Campbell:":[622],"Infinity":[623],"Pharmaceuticals,":[624,628,632,636,640,644,648],"Inc.:":[625,629,633,637,641,645,649],"Employment.":[626,630,634,638,642,646,650],"Thompson:Infinity":[627],"Villegas:Infinity":[631],"Proctor:Infinity":[635],"McGovern:Infinity":[639],"Kutok:Infinity":[643],"Stern:Infinity":[647]},"counts_by_year":[{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}